2 402

Cited 24 times in

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

DC FieldValueLanguage
dc.contributor.author김윤재-
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.contributor.author정재복-
dc.date.accessioned2015-04-24T16:21:26Z-
dc.date.available2015-04-24T16:21:26Z-
dc.date.issued2009-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/103377-
dc.description.abstractPURPOSE: There is no effective salvage regimen for failed gemcitabine-based chemotherapy. This study evaluated the efficacy and toxicity of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. METHODS: Between January 2004 and December 2007, 28 patients with pancreatic cancer previously treated with gemcitabine-based chemotherapy were enrolled. 5-Fluorouracil 1,000 mg/m(2) was infused (days 1, 2, and 3) and paclitaxel 175 mg/m(2) (day 1) was administered every 4 weeks. The primary endpoint of this study was efficacy and toxicity and the secondary endpoint was time to progression and overall survival. RESULTS: A total of 75 cycles were given, for a mean of 2.68 cycles per patient. The response could be evaluated in 20 patients. Two patients (10%) obtained a partial response, and four patients (20%) had stable disease. The median time to progression and overall survival was 2.5 and 7.6 months, respectively. Grade 3/4 hematological toxicity included neutropenia in six patients (21.4%), anemia in one (3.6%), and thrombocytopenia in one (3.6%). One (3.6%) patient experienced grade 4 neuropathy, and two (7.2%) patients experienced grade 3 diarrhea. CONCLUSION: The 5-fluorouracil and paclitaxel combination treatment seems to be effective in patients with advanced pancreatic cancer that did not respond to a gemcitabine-based regimen.-
dc.description.statementOfResponsibilityopen-
dc.format.extent529~533-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDeoxycytidine/therapeutic use-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHPancreatic Neoplasms/drug therapy*-
dc.titlePhase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYoon Jae Kim-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorJae Bock Chung-
dc.contributor.googleauthorSi Young Song-
dc.identifier.doi10.1007/s00280-008-0822-7-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00792-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.contributor.localIdA03706-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid18766341-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00280-008-0822-7-
dc.subject.keywordPancreatic cancer-
dc.subject.keywordPaclitaxel-
dc.subject.keyword5-Fluorouracil-
dc.subject.keywordGemcitabine-
dc.contributor.alternativeNameKim, Yoon Jae-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.affiliatedAuthorKim, Yoon Jae-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.contributor.affiliatedAuthorChung, Jae Bock-
dc.citation.volume63-
dc.citation.number3-
dc.citation.startPage529-
dc.citation.endPage533-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.63(3) : 529-533, 2009-
dc.identifier.rimsid37303-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.